ESC Congress 2011

27 - 31 August 2011, Paris - France

Session Details

Hot Line I - Cardiovascular risk and complications
Sun 28 Aug 11:00 - 12:30 Unknown Hot Line, Scene@ESC - Sessions to be replayed, Webcast Paris - Zone F
Chairpersons: Michel KOMAJDA (Paris, FR), Michael BOEHM (Homburg/Saar, DE)

Abstract Slides/e-posters Video Report

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
11:00407PURE: The prevention gaps in 17 low, middle and high income countries involving over 150,000 peopleSalim YUSUF (Hamilton, CA)
11:13408Discussant - PURE: The prevention gaps in 17 low, middle and high income countries involving over 150,000 peopleAldo Pietro MAGGIONI (Florence, IT)
11:18409HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery diseaseUlrich LAUFS (Homburg, DE)
11:31410Discussant - HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery diseasePhilip BARTER (Sydney, AU)
11:36411dal-VESSEL: Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease - the dal-VESSEL trialThomas Felix LUSCHER (Zurich, CH)
11:49412Discussant - dal-VESSEL: Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease - the dal-VESSEL trialKeith FOX (Edinburgh, GB)
11:54413ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin for prevention of stroke and systemic embolism in 18,202 patients with atrial fibrillation: primary results of the ARISTOTLE trialChristopher B GRANGER (Durham, US)
12:07414Discussant - ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin for prevention of stroke and systemic embolism in 18,202 patients with atrial fibrillation: primary results of the ARISTOTLE trialMichael D EZEKOWITZ (Villanova, US)
12:12415CORP: COlchicine for Recurrent Pericarditis (CORP). A multicenter, double-blind, randomized, controlled trialMassimo IMAZIO (Torino, IT)
12:25416Discussant - CORP: COlchicine for Recurrent Pericarditis (CORP). A multicenter, double-blind, randomized, controlled trialAndre KEREN (Jerusalem, IL)